• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低剂量白细胞介素-2负载纳米颗粒对实验性诱导的1型糖尿病中自然杀伤细胞和调节性T细胞表达的影响

Low-dose interleukin-2-loaded nanoparticle effect on NK and T-reg cell expression in experimentally induced type 1 diabetes mellitus.

作者信息

Aboelnazar Salma, Ghoneim Hossam, Moaaz Mai, Bahgat Eman Taha, Shalaby Thanaa

机构信息

Immunology Department, Medical Research Institute, University of Alexandria, Alexandria, Egypt.

Department of Immunology and Allergy, Medical Research Institute, University of Alexandria, Alexandria, Egypt.

出版信息

Prz Gastroenterol. 2021;16(1):67-82. doi: 10.5114/pg.2021.104737. Epub 2021 Mar 26.

DOI:10.5114/pg.2021.104737
PMID:33986891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8112267/
Abstract

INTRODUCTION

Type 1 diabetes mellitus is an autoimmune disorder characterized by inflammatory damage to pancreatic β cells resulting in loss of insulin secretion. In autoimmune type 1 diabetes mellitus (T1D) natural killer cells (NK) initiate pancreatic islets cell lyses in autoimmune T1D. Loss of T regulatory cells (Treg) at disease onset facilitates the activation and accumulation of NKs in the pancreatic microenvironment. A proper low-dose interleukin 2 (IL-2) could enhance Tregs and enforce control and regulation of pro-inflammatory NKs.

AIM

This relation needs to be studied to improve therapeutic strategies aimed at resetting the balance between Tregs and proinflammatory cells.

MATERIAL AND METHODS

We used novel formulations of low-dose IL-2 loaded on chitosan nanoparticles. The study included 116 T1D BALB/c mice experimentally induced by streptozotocin, divided into groups. Their splenocytes were maintained in a short-term culture for assessment of expression of CD4+FOXP3+ Treg and NKp46+NK by both flow cytometry and enzyme-linked immunoassay (ELISA). Morphological, immunohistochemical, and morphometrical analyses were done. suppressor assay was used to assess the suppressor effect of Treg cells after exogenous IL-2 treatment.

RESULTS

NK cell expression, NKp46 level, and NK cell functions were modulated more in mice injected with IL-2-loaded chitosan nanoparticles than in other groups. A statistical inverse correlation was found between Treg and NK cell expression in IL-2-loaded chitosan with 0.3 µIU ( = 0.047), and this correlation was related to FOXP3 expression on Treg cells. The modified expression of NK and NKp46 was noticed in mice injected with 0.3 µIU for longer duration (3 weeks) ( < 0.001), but the NK functions did not show any significant changes with prolonged treatment.

CONCLUSIONS

Prolonged administration of low-dose IL-2 results in the vigorous expression of NKp46, indicating a significant role of Tregs in NK stimulation and motivation. Low-dose IL-2 selectively modulates NKp46 NK and FOXP3+ Tregs and increases their expression.

摘要

引言

1型糖尿病是一种自身免疫性疾病,其特征是胰腺β细胞受到炎症损伤,导致胰岛素分泌丧失。在自身免疫性1型糖尿病(T1D)中,自然杀伤细胞(NK)引发自身免疫性T1D中的胰岛细胞溶解。疾病发作时调节性T细胞(Treg)的丧失促进了NK细胞在胰腺微环境中的激活和积累。适当的低剂量白细胞介素2(IL-2)可以增强Treg细胞,并加强对促炎性NK细胞的控制和调节。

目的

需要研究这种关系,以改进旨在重置Treg细胞和促炎细胞之间平衡的治疗策略。

材料和方法

我们使用了负载在壳聚糖纳米颗粒上的低剂量IL-2的新型制剂。该研究包括116只经链脲佐菌素实验诱导的T1D BALB/c小鼠,分为几组。通过流式细胞术和酶联免疫吸附测定(ELISA)对它们的脾细胞进行短期培养,以评估CD4+FOXP3+ Treg细胞和NKp46+NK细胞的表达。进行了形态学、免疫组织化学和形态计量学分析。采用抑制试验评估外源性IL-2处理后Treg细胞的抑制作用。

结果

与其他组相比,注射负载IL-2的壳聚糖纳米颗粒的小鼠中NK细胞表达、NKp46水平和NK细胞功能的调节更为明显。在负载0.3 μIU IL-2的壳聚糖中,Treg细胞和NK细胞表达之间存在统计学上的负相关(r = 0.047),这种相关性与Treg细胞上的FOXP3表达有关。在注射0.3 μIU持续较长时间(3周)的小鼠中,观察到NK和NKp46的表达发生改变(P < 0.001),但长期治疗后NK细胞功能未显示任何显著变化。

结论

长期给予低剂量IL-2会导致NKp46的强烈表达,表明Treg细胞在NK细胞的刺激和激活中起重要作用。低剂量IL-2选择性调节NKp46+NK细胞和FOXP3+ Treg细胞,并增加它们的表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/611bedd13cec/PG-16-43618-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/1952abf1b0f2/PG-16-43618-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/50463b899f7d/PG-16-43618-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/e400f756e553/PG-16-43618-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/b635c35ace80/PG-16-43618-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/6397d0d27e90/PG-16-43618-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/ad15667086c6/PG-16-43618-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/d6d91c966d64/PG-16-43618-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/b0ea751cc391/PG-16-43618-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/2e35057aafbe/PG-16-43618-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/c2e629cf2829/PG-16-43618-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/081c64f991ce/PG-16-43618-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/ff404e4bed20/PG-16-43618-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/534499f5b942/PG-16-43618-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/7476007e91b9/PG-16-43618-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/86331d46adee/PG-16-43618-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/612f495cff93/PG-16-43618-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/c7e3c5a2a5af/PG-16-43618-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/3519bc97ccca/PG-16-43618-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/e112ce992825/PG-16-43618-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/611bedd13cec/PG-16-43618-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/1952abf1b0f2/PG-16-43618-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/50463b899f7d/PG-16-43618-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/e400f756e553/PG-16-43618-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/b635c35ace80/PG-16-43618-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/6397d0d27e90/PG-16-43618-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/ad15667086c6/PG-16-43618-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/d6d91c966d64/PG-16-43618-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/b0ea751cc391/PG-16-43618-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/2e35057aafbe/PG-16-43618-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/c2e629cf2829/PG-16-43618-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/081c64f991ce/PG-16-43618-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/ff404e4bed20/PG-16-43618-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/534499f5b942/PG-16-43618-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/7476007e91b9/PG-16-43618-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/86331d46adee/PG-16-43618-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/612f495cff93/PG-16-43618-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/c7e3c5a2a5af/PG-16-43618-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/3519bc97ccca/PG-16-43618-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/e112ce992825/PG-16-43618-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/8112267/611bedd13cec/PG-16-43618-g020.jpg

相似文献

1
Low-dose interleukin-2-loaded nanoparticle effect on NK and T-reg cell expression in experimentally induced type 1 diabetes mellitus.低剂量白细胞介素-2负载纳米颗粒对实验性诱导的1型糖尿病中自然杀伤细胞和调节性T细胞表达的影响
Prz Gastroenterol. 2021;16(1):67-82. doi: 10.5114/pg.2021.104737. Epub 2021 Mar 26.
2
Effect of low dose IL-2 loaded chitosan nanoparticles on natural killer and regulatory T cell expression in experimentally induced autoimmune type 1 diabetes mellitus.低剂量白细胞介素-2负载壳聚糖纳米颗粒对实验性诱导的自身免疫性1型糖尿病中自然杀伤细胞和调节性T细胞表达的影响
Cent Eur J Immunol. 2020;45(4):382-392. doi: 10.5114/ceji.2020.103412. Epub 2021 Jan 30.
3
Modulatory effect of interleukin-2 loaded chitosan nano sphere on regulatory T cell activity in streptozotocin-induced diabetic mice.载白细胞介素-2壳聚糖纳米球对链脲佐菌素诱导的糖尿病小鼠调节性 T 细胞活性的调节作用。
Int Immunopharmacol. 2024 May 10;132:112019. doi: 10.1016/j.intimp.2024.112019. Epub 2024 Apr 9.
4
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.1型糖尿病患者单次注射白细胞介素-2后的调节性T细胞反应:一项非随机、开放标签、适应性剂量探索试验
PLoS Med. 2016 Oct 11;13(10):e1002139. doi: 10.1371/journal.pmed.1002139. eCollection 2016 Oct.
5
The effect of IL-2, IL-12 and IL15 on the function of natural killer cells in children suffering from type 1 diabetes mellitus.白细胞介素-2、白细胞介素-12和白细胞介素-15对1型糖尿病患儿自然杀伤细胞功能的影响。
Pediatr Endocrinol Diabetes Metab. 2013;19(3):91-5.
6
Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.突变型 von Hippel-Lindau-肾细胞癌 (RCC) 可促进患者特异性自然杀伤 (NK) 细胞的细胞毒性。
J Exp Clin Cancer Res. 2018 Dec 4;37(1):297. doi: 10.1186/s13046-018-0952-7.
7
Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.低剂量白细胞介素-2用于新诊断的1型糖尿病儿童:一项I/II期随机、双盲、安慰剂对照、剂量探索性研究。
Diabetologia. 2020 Sep;63(9):1808-1821. doi: 10.1007/s00125-020-05200-w. Epub 2020 Jul 1.
8
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.低剂量白细胞介素-2可在1型糖尿病患者中营造出一种剂量依赖性的调节性T细胞调节环境。
J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.
9
IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice.IL-15 促进调节性 T 细胞的功能,并防止 NK 细胞耗竭的 NOD 小鼠发生糖尿病。
Clin Immunol. 2010 Feb;134(2):130-9. doi: 10.1016/j.clim.2009.09.011. Epub 2009 Oct 28.
10
Expression of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin 10 and Transforming Growth Factor β in Newly Diagnosed Type 2 Diabetic Patients.新诊断2型糖尿病患者中CD4+CD25+Foxp3+调节性T细胞、白细胞介素10及转化生长因子β的表达
Exp Clin Endocrinol Diabetes. 2018 Feb;126(2):96-101. doi: 10.1055/s-0043-113454. Epub 2017 Sep 27.

引用本文的文献

1
Lower percentages of natural killer cells in children with type 1 diabetes and their siblings.1 型糖尿病患儿及其兄弟姐妹的自然杀伤细胞比例较低。
Pediatr Endocrinol Diabetes Metab. 2023;29(4):214-224. doi: 10.5114/pedm.2023.132029.
2
Interleukin-2 promotes pegylated interferon alpha for hepatitis B surface antigen loss: A retrospective pragmatic clinical study at the Fourth Affiliated Hospital of Zhejiang University Medical College.白细胞介素-2联合聚乙二醇化干扰素α促进乙肝表面抗原消失:浙江大学医学院附属第四医院的一项回顾性实用临床研究
Health Sci Rep. 2022 Nov 14;5(6):e932. doi: 10.1002/hsr2.932. eCollection 2022 Nov.
3

本文引用的文献

1
Islet autoantibody positivity in overweight and obese adults with type 2 diabetes.超重和肥胖 2 型糖尿病患者的胰岛自身抗体阳性。
Autoimmunity. 2018 Dec;51(8):408-416. doi: 10.1080/08916934.2018.1547711. Epub 2019 Jan 2.
2
Childhood thyroid autoimmunity and relation to islet autoantibodies in children at risk for type 1 diabetes in the diabetes prediction in skåne (DiPiS) study.在斯科讷糖尿病预测研究(DiPiS)中,自身免疫性甲状腺疾病与儿童期 1 型糖尿病高危人群胰岛自身抗体的关系。
Autoimmunity. 2018 Aug;51(5):228-237. doi: 10.1080/08916934.2018.1519027.
3
Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: A review.
Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1.
调节性 T 细胞在 1 型糖尿病中的潜在治疗应用。
Int J Mol Sci. 2021 Dec 30;23(1):390. doi: 10.3390/ijms23010390.
壳聚糖复合材料和壳聚糖纳米颗粒复合材料对各种药物递送系统的影响:综述
J Food Drug Anal. 2015 Dec;23(4):619-629. doi: 10.1016/j.jfda.2014.10.008. Epub 2014 Dec 4.
4
Low-dose IL-2 selectively activates subsets of CD4 Tregs and NK cells.低剂量白介素 2 选择性地激活 CD4 Treg 和自然杀伤细胞亚群。
JCI Insight. 2016 Nov 3;1(18):e89278. doi: 10.1172/jci.insight.89278.
5
DLS and zeta potential - What they are and what they are not?动态光散射(DLS)和 Zeta 电位:它们是什么,又不是什么?
J Control Release. 2016 Aug 10;235:337-351. doi: 10.1016/j.jconrel.2016.06.017. Epub 2016 Jun 10.
6
The genetic and regulatory architecture of ERBB3-type 1 diabetes susceptibility locus.ERBB3 型 1 型糖尿病易感性位点的遗传与调控结构
Mol Cell Endocrinol. 2016 Jan 5;419:83-91. doi: 10.1016/j.mce.2015.10.002. Epub 2015 Oct 9.
7
Therapeutic window of interleukin-2 for autoimmune diseases.白细胞介素-2在自身免疫性疾病中的治疗窗。
Diabetes. 2015 Jun;64(6):1912-3. doi: 10.2337/db15-0188.
8
Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition.2型糖尿病:从一种代谢紊乱到一种炎症状态。
World J Diabetes. 2015 May 15;6(4):598-612. doi: 10.4239/wjd.v6.i4.598.
9
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.低剂量白细胞介素-2 治疗自身免疫和炎症性疾病的前景。
Nat Rev Immunol. 2015 May;15(5):283-94. doi: 10.1038/nri3823. Epub 2015 Apr 17.
10
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.低剂量白细胞介素-2可在1型糖尿病患者中营造出一种剂量依赖性的调节性T细胞调节环境。
J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.